Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Raltegravir potassium
Drug ID BADD_D01906
Description Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.
Indications and Usage For the treatment of HIV-1 infection in conjunction with other antiretrovirals.
Marketing Status approved
ATC Code J05AJ01
DrugBank ID DB06817
KEGG ID D07133
MeSH ID D000068898
PubChem ID 23668479
TTD Drug ID D0I1FQ
NDC Product Code 62331-055; 67317-0001; 67651-0275; 70600-028; 50473-0001; 67317-0031; 65977-0129; 67651-0276; 65015-841; 67651-0274
UNII 43Y000U234
Synonyms Raltegravir Potassium | Potassium, Raltegravir | Raltegravir | MK 0518 | 0518, MK | MK0518 | MK-0518 | Isentress
Chemical Information
Molecular Formula C20H20FKN6O5
CAS Registry Number 871038-72-1
SMILES CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)[O-])C(=O)NCC3=CC=C(C=C3)F.[K+]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abnormal behaviour19.01.01.001--Not Available
Anal cancer16.13.05.001; 07.21.05.001--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Ill-defined disorder08.01.03.049--Not Available
Inner ear disorder04.04.02.002--Not Available
Polyp16.02.02.005; 08.01.06.010--Not Available
Blood disorder01.05.01.004--Not Available
Autoimmune disorder10.04.04.003--
Psychotic disorder19.03.01.002--
Hepatobiliary disease09.01.08.003--Not Available
Hyperlipidaemia14.08.03.001--
Renal impairment20.01.03.010--Not Available
Lipohypertrophy14.08.04.009; 23.07.01.005--
Poor quality sleep17.15.04.002; 19.02.05.005--Not Available
Chronic kidney disease20.01.03.017--
Waist circumference increased13.15.01.033--Not Available
Suicidal behaviour19.12.01.006--Not Available
Anorectal discomfort07.03.03.003--Not Available
Fasting26.01.02.001--Not Available
Hepatic cancer16.07.02.004; 09.04.02.008--Not Available
Hepatocellular carcinoma16.07.02.005; 09.04.02.010--Not Available
Graves' disease10.04.08.014; 06.09.04.009; 05.02.02.009--Not Available
Mandibular mass15.03.05.021; 08.03.05.011--Not Available
The 9th Page    First    Pre   9    Total 9 Pages